M&A

News

Biogen offers to buy out wilting Sage for $442 million

Biogen has offered to buy all the shares in Sage Therapeutics that it doesn't already own, taking control of their novel antidepressant Zurzuvae.

News

Is GSK prepping a $1bn takeover bid for IDRx?

GSK is reportedly in negotiations about a $1bn deal to acquire IDRx and its targeted therapy for a form of rare gastrointestinal tumour.

News

Galapagos' chief executive Paul Stoffels

Galapagos unveils plan to split, hiving off its drugs unit

Belgian biotech Galapagos is mixing things up again via a plan to split in two, separating its drug development and cell therapy operations.

Market Access

Graphic of an upward trajectory arrow with woman and telescope atop

The biopharma outlook for 2025: Opportunities and challenges

With the Federal Reserve poised to implement interest rate cuts (albeit fewer than earlier forecasts assumed) and FTC leadership turnover anticipated, there may be broader shifts in how cap

News

London-listed Poolbeg discussing Hookipa merger

The UK's Poolbeg Pharma has disclosed that it is in talks over a possible takeover by Hookipa, an Austrian biotech that is listed on the Nasdaq.

News

Regeneron builds in eye disease tech with Oxular takeover

Regeneron has bought Oxular, a UK specialist in retinal diseases, in a move that bolsters its already strong position in ophthalmology therapies.

Biogen offers to buy out wilting Sage for $442 million

Is GSK prepping a $1bn takeover bid for IDRx?

Galapagos unveils plan to split, hiving off its drugs unit

The biopharma outlook for 2025: Opportunities and challenges

London-listed Poolbeg discussing Hookipa merger

Regeneron builds in eye disease tech with Oxular takeover

Immunovant's thyroid eye disease drug flunks pivotal trials

Using AI-driven synthetic personas to take your insights fur...

M&A

Editor's Picks